• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD47 在骨髓增生异常综合征的造血细胞上表达异常。

CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome.

机构信息

Hematology Department, General Hospital, Tianjin Medical University, Tianjin, China.

出版信息

Leuk Res. 2013 Aug;37(8):907-10. doi: 10.1016/j.leukres.2013.04.008. Epub 2013 May 2.

DOI:10.1016/j.leukres.2013.04.008
PMID:23642736
Abstract

The increased LSC in MDS has correlation with the progression to AML, which the mechanism of immune evasion is unclear. Our study showed the expression of CD47 on LSC of the patients in high-risk MDS based on IPSS/WPSS score was higher than that of in low-risk MDS and controls. The level of CD47 on erythroblast of MDS patients had a significant positive correlation with their peripheral RBC count. It suggested that the proportion of CD34(+)CD38(-)CD47(+) cells increased in high-risk MDS which might protect LSC from avoiding phagocytosis, and low-expression of CD47 on erythroblast in MDS might be correlated to anemia.

摘要

骨髓增生异常综合征(MDS)中 LSC 的增加与向 AML 的进展相关,其免疫逃逸机制尚不清楚。我们的研究表明,基于 IPSS/WPSS 评分,高危 MDS 患者 LSC 上 CD47 的表达高于低危 MDS 和对照组。MDS 患者红细胞上 CD47 的水平与外周 RBC 计数呈显著正相关。这表明高危 MDS 中 CD34(+)CD38(-)CD47(+)细胞的比例增加,可能保护 LSC 免受吞噬作用,而 MDS 中红细胞上 CD47 的低表达可能与贫血相关。

相似文献

1
CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome.CD47 在骨髓增生异常综合征的造血细胞上表达异常。
Leuk Res. 2013 Aug;37(8):907-10. doi: 10.1016/j.leukres.2013.04.008. Epub 2013 May 2.
2
[Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].骨髓增生异常综合征中CD34+造血干细胞的细胞周期及增殖特性研究
Zhonghua Xue Ye Xue Za Zhi. 2004 Nov;25(11):641-4.
3
Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.急性髓系白血病中CD34+CD38-干细胞亚群上异常的标志物表达模式,使得在诊断时和缓解期均能够区分恶性干细胞亚群与正常干细胞亚群。
Leukemia. 2007 Aug;21(8):1700-7. doi: 10.1038/sj.leu.2404754. Epub 2007 May 24.
4
Phagocytosis checkpoints on hematopoietic stem cells in patients with myelodysplastic syndromes.骨髓增生异常综合征患者造血干细胞的吞噬作用检查点。
Asia Pac J Clin Oncol. 2022 Apr;18(2):e119-e128. doi: 10.1111/ajco.13566. Epub 2021 Jun 21.
5
Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.骨髓增生异常综合征中未成熟造血祖细胞CD34+/CD38dim增加。
Cytometry B Clin Cytom. 2006 Mar;70(2):63-70. doi: 10.1002/cyto.b.20088.
6
[Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].骨髓增生异常综合征患者CD34+骨髓细胞上膜造血细胞因子受体的分化与表达
Zhonghua Yi Xue Za Zhi. 2011 Jan 25;91(4):234-8.
7
[STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].骨髓增生异常综合征患者CD34(+)CD38(-)CD123(+)骨髓细胞中的STAT5磷酸化
Zhonghua Xue Ye Xue Za Zhi. 2012 Jun;33(6):480-3.
8
Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes.骨髓增生异常综合征中造血细胞上CD25表达异常。
Leuk Res. 2018 Apr;67:12-16. doi: 10.1016/j.leukres.2017.11.010. Epub 2017 Dec 15.
9
[Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].骨髓增生异常综合征患者骨髓髓系细胞分化抗原的表达及其临床意义
Zhonghua Yi Xue Za Zhi. 2010 Mar 16;90(10):672-7.
10
GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.GATA-1转录因子在骨髓增生异常综合征的骨髓造血祖细胞CD34(+)和红系细胞CD71(+)中上调。
Am J Hematol. 2007 Oct;82(10):887-92. doi: 10.1002/ajh.20993.

引用本文的文献

1
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.急性髓系白血病治疗的变革:基于免疫疗法的系统综述
Discov Oncol. 2025 Jan 26;16(1):89. doi: 10.1007/s12672-025-01797-9.
2
PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages.程序性死亡受体配体1(PD-L1)单克隆抗体通过调节肿瘤相关巨噬细胞中的CD47/含Src同源2结构域蛋白酪氨酸磷酸酶2(SHP2)/信号调节蛋白α(SIRPα)/脾酪氨酸激酶(SYK)/Fcγ受体信号通路减轻心肌梗死所致的左心室功能损伤。
Sci Rep. 2025 Jan 17;15(1):2303. doi: 10.1038/s41598-024-85065-w.
3
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.
用于急性髓系白血病的单克隆抗体免疫疗法:一项正在进行的工作。
Cancers (Basel). 2023 Oct 19;15(20):5060. doi: 10.3390/cancers15205060.
4
Emerging phagocytosis checkpoints in cancer immunotherapy.癌症免疫治疗中的新兴吞噬检查点。
Signal Transduct Target Ther. 2023 Mar 7;8(1):104. doi: 10.1038/s41392-023-01365-z.
5
The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.免疫的阴阳两面:不同风险分层骨髓增生异常综合征中的免疫失调。
Front Immunol. 2022 Sep 23;13:994053. doi: 10.3389/fimmu.2022.994053. eCollection 2022.
6
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.免疫检查点抑制在急性髓系白血病和骨髓增生异常综合征中的作用。
Cells. 2022 Jul 20;11(14):2249. doi: 10.3390/cells11142249.
7
Stem Cells in the Myelodysplastic Syndromes.骨髓增生异常综合征中的干细胞
Front Aging. 2021 Jul 16;2:719010. doi: 10.3389/fragi.2021.719010. eCollection 2021.
8
Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome.骨髓增生异常综合征患者的肠道微生物组和血浆代谢组分析。
Oxid Med Cell Longev. 2022 May 9;2022:1482811. doi: 10.1155/2022/1482811. eCollection 2022.
9
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.抗 CD47 单克隆抗体 CC-90002 治疗复发/难治性急性髓系白血病和高危骨髓增生异常综合征患者的 1 期研究。
Ann Hematol. 2022 Mar;101(3):557-569. doi: 10.1007/s00277-021-04734-2. Epub 2022 Jan 4.
10
Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia.通过阻断CD47来利用巨噬细胞:对急性髓系白血病的意义
Cancers (Basel). 2021 Dec 13;13(24):6258. doi: 10.3390/cancers13246258.